Swee Yeok Chu

Biomedical Sciences Investment Fund Pte Ltd seeks investment opportunities in Singapore, Europe, Asia and the US. The fund targets companies operating in the fields of biotechnology, pharmaceuticals and medical technology companies. It provides financing for early stage capital requirements.

EDB Investments Pte Ltd (EDB Investments) is a Venture Capital firm founded in 1991. The firm is headquartered in Singapore.

Silecs International Pte Ltd. manufactures and markets siloxane polymers for microelectronics sector. Its products include semiconductor mask manufacturing, fabrication and packaging. The compnay was founded by Juha Rantala and Kokko Jaakko in 2000 and is headquartered in Singapore.

Bio*One Capital Pte Ltd (Bio*One Capital) is a venture capital subsidiary of EDB Investments Pte Ltd founded in 1991. The firm is headquartered in Singapore.

Singapore Suzhou Township Development Pte Ltd. provides real estates services. It also engages in harbor and related offshore structure construction. The company is headquartered in Singapore.

MerLion Pharmaceuticals Pte Ltd. provides drug discovery and development services. It focuses on developing its lead antibacterial candidate, finafloxacin, through early and mid-stage clinical trials. The company was founded in 2002 and is headquartered in Singapore.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.